Literature DB >> 11767031

Long-term assessment of combined vitamin A and E treatment for the prevention of retinal degeneration in abetalipoproteinaemia and hypobetalipoproteinaemia patients.

I Chowers1, E Banin, S Merin, M Cooper, E Granot.   

Abstract

PURPOSE: To assess the long-term efficacy of combined vitamin A and E treatment in preventing retinal degeneration in patients with abetalipoproteinaemia (ABL) or homozygous hypobetalipoproteinaemia (HBL).
METHODS: Ten patients with ABL and 3 with homozygous HBL who were treated with oral supplements of vitamins A and E were studied. Systemic, ophthalmological and electroretinographic follow-up for a mean of 11.7 years (range 4-20 years) after onset of treatment was evaluated.
RESULTS: Despite vitamin A and E treatment, 7 of 10 patients who began treatment prior to 2 years of age and all 3 patients who began treatment later in life manifested unusual fundoscopic pigmentary changes over time. At the end of follow-up, 11 of 13 patients had subnormal mixed cone-rod electroretinogram amplitudes. Seven of 10 patients for whom perimetry was available had mild to severe constriction of the visual fields.
CONCLUSIONS: Combined oral vitamin A and E supplementation that is initiated prior to 2 years of age can markedly attenuate the severe retinal degeneration that is associated with untreated ABL or homozygous HBL. Yet, fundoscopic and functional retinal changes do occur despite early initiation of vitamin treatment. Therefore, the adequacy of the present treatment protocol for ABL and homozygous HBL should be re-evaluated.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11767031     DOI: 10.1038/eye.2001.167

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  26 in total

1.  Clinical utility gene card for: Abetalipoproteinaemia.

Authors:  John R Burnett; Damon A Bell; Amanda J Hooper; Robert A Hegele
Journal:  Eur J Hum Genet       Date:  2012-02-29       Impact factor: 4.246

Review 2.  Ophthaproblem. Vitamin A and vitamin E.

Authors:  Shaun Segal; Sanjay Sharma
Journal:  Can Fam Physician       Date:  2005-08       Impact factor: 3.275

3.  Clinical utility gene card for: Familial Hypobetalipoproteinaemia (APOB).

Authors:  John R Burnett; Damon A Bell; Amanda J Hooper; Robert A Hegele
Journal:  Eur J Hum Genet       Date:  2012-05-16       Impact factor: 4.246

4.  Microsomal triglyceride transfer protein gene mutations in Turkish children: A novel mutation and clinical follow up.

Authors:  Mehmet Gündüz; Eda Özaydın; Müge Büyüktaşlı Atar; Nevra Koç; Ceyda Kırsaçlıoğlu; Gülşen Köse; Angelo Baldassare Cefalù; Maurizio Averna; Patrizia Tarugi
Journal:  Indian J Gastroenterol       Date:  2016-05-10

5.  Clinical utility gene card for: Familial hypobetalipoproteinaemia (APOB)--Update 2014.

Authors:  John R Burnett; Damon A Bell; Amanda J Hooper; Robert A Hegele
Journal:  Eur J Hum Genet       Date:  2014-10-22       Impact factor: 4.246

6.  Clinical utility gene card for: Abetalipoproteinaemia--Update 2014.

Authors:  John R Burnett; Damon A Bell; Amanda J Hooper; Robert A Hegele
Journal:  Eur J Hum Genet       Date:  2014-10-22       Impact factor: 4.246

Review 7.  Abetalipoproteinemia and homozygous hypobetalipoproteinemia: a framework for diagnosis and management.

Authors:  Jooho Lee; Robert A Hegele
Journal:  J Inherit Metab Dis       Date:  2013-11-28       Impact factor: 4.982

8.  Common and rare gene variants affecting plasma LDL cholesterol.

Authors:  John R Burnett; Amanda J Hooper
Journal:  Clin Biochem Rev       Date:  2008-02

Review 9.  Aging, age-related macular degeneration, and the response-to-retention of apolipoprotein B-containing lipoproteins.

Authors:  Christine A Curcio; Mark Johnson; Jiahn-Dar Huang; Martin Rudolf
Journal:  Prog Retin Eye Res       Date:  2009-08-19       Impact factor: 21.198

Review 10.  Dosage and formulation issues: oral vitamin E therapy in children.

Authors:  Tone Westergren; Betty Kalikstad
Journal:  Eur J Clin Pharmacol       Date:  2009-10-13       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.